gsk-1521498
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00857883)
Timeline
Indications
Studied for
Mechanism of action
- Mu opioid receptorANTAGONIST
OPRM antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1- Mol. weight
- 402.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297383 ↗
Also known as
- gsk1521498
- gsk1521498
- gsk1521498
- gsk 1521498
- gsk-1521498
- gsk-1521498
- n-((3,5-difluoro-3'-(1h-1,2,4-triazol-3-yl)-4-biphenylyl)methyl)-2,3-dihydro-1h-inden-2-amine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01738867 | Phase 1 | Dec 12, 2012 | GlaxoSmithKline |
| NCT01366573 | Phase 1 | May 1, 2011 | GlaxoSmithKline, University of Cambridge |
| NCT01195792 | Phase 2 | Sep 1, 2010 | GlaxoSmithKline |
| NCT00976105 | Phase 1 | Sep 22, 2009 | GlaxoSmithKline |
| NCT00976066 | Phase 1 | Jun 15, 2009 | GlaxoSmithKline |
| NCT00857883 | Phase 1 | Nov 1, 2008 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2008 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1